MAP US Trial – Crohn’s Disease
The sponsor for this clinical trial, Redhill Biopharma, has developed a new drug called RHB-104 that is comprised of a triple antibiotic therapy targeting the specimen Mycobacterium Avium Paratuberculosis (MAP) in patients with moderately to severely active Crohn’s disease. This study is aimed at determining if there is a relationship between MAP infection and Crohn’s disease. Patients enrolled will follow a dose-escalation therapy with the medication in pill form taken at home.
In order to participate you must meet the following criteria:
- Have been diagnosed with Crohn’s disease for at least 6 months.
Are currently receiving treatment with at least one of the following:
- Oral 5-ASA compounds
- Azathioprine or 6-mercaptopurine (6-MP) or methotrexate
- Infliximab/Remicade of Adalimumab/Humira
You will be excluded from the study if any of the following criteria apply to you:
- Have short bowel syndrome/short gut syndrome.
- Have a history of unstable cardiac syndromes or history of drug/alcohol abuse within the last three years.
This is a partial list of elgibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.